AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics (ANGO) reported net sales of $80.9 million for the three months ended August 31, 2026, up 6.9% from $75.7 million a year earlier. Gross margin rose to 59.4% from 55.3%, an increase of 410 basis points. Med Tech sales increased 13.2%, while Med Device sales increased 1.4%.
Net loss narrowed to $7.1 million ($0.17 per diluted share) from $10.9 million ($0.26) a year earlier. Operating cash use was $15.3 million, compared with $15.9 million, and cash was $34.0 million as of August 31, 2026, down from $53.9 million at May 31, 2026. Management said current cash on hand provides sufficient liquidity for anticipated capital needs for at least the next 12 months. No amounts were outstanding under its $25.0 million secured revolving credit facility as of August 31, 2026.
The modified manufacturing restructuring plan has estimated costs of $33.4 million to $38.4 million, and activities are expected to be completed in the second quarter of fiscal 2027. AngioDynamics announced Eric Honroth’s appointment as President and Chief Executive Officer and a Board member, effective November 2, 2026; Jim Clemmer will depart the Board that day.
AngioDynamics, Inc. asks shareholders to elect Eileen O. Auen and Jan Stern Reed as Class II directors, ratify Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending May 31, 2027, approve named executive compensation on an advisory basis, and approve an amendment increasing shares reserved under the 2020 Equity Incentive Plan from 9,050,000 to 10,050,000. The Annual Meeting is November 17, 2026, at noon Eastern Time, by webcast only; shareholders of record on September 18, 2026, may vote. The Board recommends “FOR” all four proposals.
For the year ended May 31, 2026, revenue increased 9.5% on a GAAP as reported basis; Med Tech grew 18.4% and Med Device increased 2.6%. Howard W. Donnelly plans to retire as Board Chair at the meeting, after which Eileen O. Auen will serve as independent, non-executive Chair. Eric Honroth will succeed President and CEO James C. Clemmer effective November 2, 2026. Clemmer will provide consulting services until the first anniversary of his retirement, unless earlier terminated.
AngioDynamics reported fiscal 2027 first-quarter net sales of $80.9 million, up 6.9% year over year. Med Tech sales increased 13.2% to $39.9 million, while Med Device sales rose 1.4% to $41.0 million. Gross margin was 59.4%, 410 basis points higher than a year earlier; GAAP net loss was $7.1 million versus $10.9 million, and adjusted EBITDA was $5.0 million versus $2.2 million. Operating cash use was $15.3 million; cash was $34.0 million with no debt at August 31, 2026.
The company reiterated fiscal 2027 guidance and expects gross margin to be lower in the second half than in the first half. Eric Honroth was appointed President and Chief Executive Officer effective November 2, 2026, succeeding Jim Clemmer, who will remain as an executive advisor. The FDA approved the IDE for the RELIEF feasibility study of NanoKnife for benign prostatic hyperplasia; the study is designed for 40 subjects at up to five U.S. sites, with a six-month symptom-score endpoint.
AngioDynamics appointed Eric Honroth as president and chief executive officer effective November 2, 2026, succeeding James C. Clemmer, who will retire from those roles and leave the board. Honroth is also to join the board on that date, contingent on beginning CEO service and Clemmer's board retirement. Honroth most recently served as President Life Science at Getinge AB from 2018 to 2026.
Honroth's agreement sets a $735,000 annual base salary and a target annual bonus of 95% of salary. Contingent on starting the role, he will receive a $1,487,116 long-term incentive award split equally between restricted stock units and performance share units, a $450,000 replacement restricted-stock-unit award vesting on the first and second anniversaries, and a $350,000 cash sign-on bonus. The agreement also provides a $10,000 monthly commuting and temporary living allowance for up to 24 months and a $24,000 annual automobile allowance. Clemmer will consult through the first anniversary of the effective date, unless earlier terminated, for $30,000 monthly. Retention agreements provide for equity acceleration for covered executives under stated employment conditions.
AngioDynamics amended its fiscal 2026 annual report solely to add inline XBRL tagging to Part III information that was inadvertently incomplete; it says no other information was changed. Performance against fiscal 2026 cash-incentive targets included net sales of $320.2 million versus a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. The compensation committee credited 100% attainment for corporate objectives, resulting in cash incentive payouts equal to 180% of target for each named executive officer.
President and Chief Executive Officer James C. Clemmer announced his intention to retire on the earlier of a successor CEO’s appointment or November 30, 2026; by mutual agreement, the date may be extended month to month until a successor is found. His transition agreement provides continued vesting of previously issued equity awards until the later of the end of his service as a consultant or director. After that, stock options and service-based restricted stock units immediately vest, while performance-based restricted stock units remain eligible to vest under their terms. For fiscal 2026, 64% of the CEO’s target total compensation was performance-based.
AngioDynamics, Inc. amended its fiscal 2026 annual report to add Part III disclosures on directors, governance and executive compensation. It states that no other items were amended or updated and that the original report otherwise remains unchanged.
For fiscal 2026, net sales were $320.2 million against a $312 million incentive target, and Adjusted EBITDA was $18.2 million against a $10.5 million target. Each of the five named executive officers received an annual cash incentive payout equal to 180% of target. Approximately 93.1% of votes cast, including abstentions, favored named executive compensation at the 2025 annual meeting; the committee kept its general approach for fiscal 2026.
Chief Executive Officer James C. Clemmer announced an intention to retire on the earlier of November 30, 2026, or the appointment of a successor, with a possible month-to-month extension by mutual agreement. Retention agreements provide Stephen A. Trowbridge, Laura Piccinini and Warren G. Nighan awards equal to 150% of base salary if they meet the stated employment condition or their position is eliminated without cause; other executive leadership team members are eligible for 50%.
AngioDynamics Inc. executive Warren Nighan Jr., SVP Quality and Regulatory, reported the sale of 23,370 shares of common stock on 2026-07-30. The reported price of $14.72 per share is a weighted average from multiple trades between $14.65 and $14.80. After this transaction, he directly holds 64,745 shares. The filing indicates the sale was not made under a Rule 10b5-1 trading plan.
AngioDynamics, Inc. is the subject of a notice covering a proposed sale of 23,370 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an indicated aggregate value of $344,004.06 as of the filing data.
The shares relate to equity awards, including 10,949 restricted stock shares granted on 07/17/2020 and 12,421 performance share units granted on 08/12/2021, identified as securities to be sold by the issuer’s insider.
AngioDynamics Inc. executive Laura Piccinini, SVP International, reported vesting of performance share units granted on July 19, 2023. A target grant of 28,336 units resulted in 8,047 common shares being issued, while 4,506 shares were withheld at $13.82 per share for taxes and the remaining units were forfeited.
Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics, had a 2023 performance share unit grant settle. A target award of 20,052 performance share units led to the issuance of 5,694 shares of common stock based on performance, with the remaining units forfeited. Of the shares issued, 1,671 were withheld at $13.82 per share to satisfy tax withholding obligations.